Camsirubicin
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Soft-tissue Sarcoma
Conditions
Advanced Soft-tissue Sarcoma
Trial Timeline
Sep 22, 2021 → May 13, 2024
NCT ID
NCT05043649About Camsirubicin
Camsirubicin is a phase 1 stage product being developed by Monopar Therapeutics for Advanced Soft-tissue Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05043649. Target conditions include Advanced Soft-tissue Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05043649 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Soft-tissue Sarcoma